• José Adão Carvalho Nascimento Júnior, Anamaria Mendonça Santos, Rafael Ciro Marques Cavalcante, Lucindo José Quintans-Júnior, Cristiani Isabel Banderó Walker, Lysandro Pinto Borges, Luiza Abrahão Frank, and Mairim Russo Serafini.
• Department of Pharmacy, Federal University of Sergipe, São Cristóvão, Sergipe, Brazil.
• Drug Dev Ind Pharm. 2021 Apr 1; 47 (4): 673-684.

PurposeThe last two decades have seen the emergence of several viral outbreaks. Some of them are the severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and severe acute respiratory syndrome 2 (SARS-CoV2) - the cause of the coronavirus disease 2019 (COVID-19). Ever, vaccines for emergency use have been authorized for the control and prevention of COVID-19. Currently, there is an urgent need to develop a vaccine for prophylaxis of COVID-19 and for other future epidemics.MethodsThis review describes patented vaccines for SARS and MERS-CoV and vaccines developed and approved for emergency use against the new coronavirus (COVID-19). The European Patent Office and the World Intellectual Property Organization were the patent databases used using specific terms. In addition, another search was carried out in the Clinical Trials in search of ongoing clinical studies focused on the COVID-19 vaccine.ResultsThe patent search showed that most vaccines are based on viral vector platforms, nucleic acids, or protein subunits. The review also includes an overview of completed and ongoing clinical trials for SARS-CoV-2 in several countries.ConclusionThe information provided here lists vaccines for other types of coronavirus that have been used in the development of vaccines for COVID-19.

12 keywords...

hide…